Welcome!

News Feed Item

NAS911 Being Evaluated as Co-Therapeutic for Treatment of Influenza

SCOTTSDALE, AZ -- (Marketwired) -- 08/06/14 -- New Amsterdam Sciences (NAS), an emerging bioscience company focused on treating respiratory illnesses, announced today the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS' lead compound NAS911 as a co-therapeutic for existing influenza antivirals currently available to flu patients. Tamiflu is presently the gold standard for prevention or inhibition of the spread of influenza virus A and B.

Studies were conducted through the Therapeutics Development Services program of the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The goal of the research is to identify and advance the development of a co-therapeutic for existing antivirals for influenza. To date, New Amsterdam Sciences has explored the use of NAS911F in a multitude of different preclinical FDA accepted influenza infection models. Studies conducted by the company through third party facilities has demonstrated that NAS911F is shown to be a more effective treatment candidate than Tamiflu in side-by-side animal model comparison studies with end points of duration of flu, symptoms and other key factors supporting the work. An upcoming planned study for NAS is a co-therapeutic study combining Roche's TamiFlu with NAS's NAS911F with expectations of data demonstrating greater efficacy of TamiFlu combined with NAS911F as a combinatory influenza treatment. "Having the development interest and support from DMID for our flu candidate is extremely promising for our prospect pharma partnerships," said Michael Wilhelm, Director of Strategic Partnering. "This aids in the advancement of the most effective flu treatments currently available or in development." NAS is confident the co-therapeutic candidate will not only be more effective at the first symptom of flu but on severe and late stage flu cases as well. The company has explored seasonal and pandemic strains, observing reductions of morbidity and mortality in all models tested. NAS is currently exploring testing with additional influenza strains, including H7N9. These studies would to further explore the ideal dosing regimen for a clinical trial, as well as defining the mechanism of action of NAS911F in these models. NAS911F is a host-targeted immunomodulatory with a significant breadth and depth of safety and efficacy in the dozens of models tested to date.

"Working with the NIH's Influenza Therapeutics Development Program is a serious boon to the development of New Amsterdam Sciences' novel influenza therapeutic, NAS911F," said Jerry Toepfer, Vice President of NAS. "We anticipate this relationship will be an enormous leverage of time and money for our research, directly leading to our clinical trial objectives."

About the National Institute of Allergy and Infectious Diseases (NIAID)

NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About New Amsterdam Sciences

New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. The company's lead compound is NAS911, which is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, radiation sickness, and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial and government markets, focusing specifically on mass casualty biodefense applications. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, BARDA, NIH and more. For additional information, please visit www.newamsterdamsciences.com.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2652208

CORPORATE CONTACT:
Investor and Corporate Relations
Michael K. Wilhelm
480-477-7735
Email Contact
Email Contact

MEDIA CONTACT:
Dan Spelling
310-838-4010
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities. In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, posited that disruption is inevitable for comp...
SYS-CON Events announced today that Datanami has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datanami is a communication channel dedicated to providing insight, analysis and up-to-the-minute information about emerging trends and solutions in Big Data. The publication sheds light on all cutting-edge technologies including networking, storage and applications, and thei...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Silicon India has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Published in Silicon Valley, Silicon India magazine is the premiere platform for CIOs to discuss their innovative enterprise solutions and allows IT vendors to learn about new solutions that can help grow their business.
Join us at Cloud Expo June 6-8 to find out how to securely connect your cloud app to any cloud or on-premises data source – without complex firewall changes. More users are demanding access to on-premises data from their cloud applications. It’s no longer a “nice-to-have” but an important differentiator that drives competitive advantages. It’s the new “must have” in the hybrid era. Users want capabilities that give them a unified view of the data to get closer to customers and grow business. The...
The Internet giants are fully embracing AI. All the services they offer to their customers are aimed at drawing a map of the world with the data they get. The AIs from these companies are used to build disruptive approaches that cannot be used by established enterprises, which are threatened by these disruptions. However, most leaders underestimate the effect this will have on their businesses. In his session at 21st Cloud Expo, Rene Buest, Director Market Research & Technology Evangelism at Ara...
"We do one of the best file systems in the world. We learned how to deal with Big Data many years ago and we implemented this knowledge into our software," explained Jakub Ratajczak, Business Development Manager at MooseFS, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), provided an overview of various initiatives to certify the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldwide re...